New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 18, 2014
18:04 EDTSHPG, ABBVAbbVie purchase of Shire worth the premium, Barron's reports
AbbVie (ABBV) did not get a bargain when it purchased Shire (SHPG). However, the deal will go a long way towards lowering AbbVie's tax burden and enlarging its portfolio, which should drive the stock price higher over the long term, Barron's reports. Reference Link
News For ABBV;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 22, 2015
18:04 EDTSHPGShire completes acquisition of NPS Pharma
Shire (SHPG) announces the successful completion of the tender offer for all of the outstanding shares of NPS Pharmaceuticals (NPSP) and the subsequent acquisition of NPS Pharma.The tender offer expired at 12:00 midnight, New York City time, at the end of Friday, February 20, and was not extended. As of the expiration of the tender offer, a total of approximately 88,869,118 common shares of NPS Pharma had been validly tendered and not withdrawn pursuant to the tender offer, representing approximately 81.7% of the outstanding common shares of NPS Pharma. All shares that were validly tendered and not withdrawn pursuant to the tender offer were accepted for payment. After the acceptance of shares that were validly tendered and not withdrawn pursuant to the tender offer, Shire completed the acquisition of NPS Pharma today through a merger of one of Shire's subsidiaries with and into NPS Pharma. In connection with the merger, all common shares of NPS Pharma that were not accepted for payment in the tender offer (excluding any shares held by NPS Pharma as treasury stock (other than any shares held in an NPS Pharma benefit plan) and any shares with respect to which the holders have properly demanded appraisal rights in accordance with Delaware law) were converted into the right to receive $46.00 per share in cash, without interest and less any applicable withholding taxes, the same price that will be paid for shares accepted for payment in the tender offer. Following completion of the merger, NPS Pharma became a wholly owned subsidiary of Shire and NPS Pharma's shares ceased to be traded on NASDAQ.
15:59 EDTSHPGValeant to buy Salix for $10.1B, FT says
Subscribe for More Information
February 20, 2015
10:33 EDTABBVBattleground update: AbbVie named top global pick at Jefferies
Subscribe for More Information
07:23 EDTABBVAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTSHPGAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
12:13 EDTABBVAbbVie increases quarterly dividend 4% to 51c per share
Subscribe for More Information
February 17, 2015
18:06 EDTABBV, SHPGPaulson & Co gives quarterly update on stakes
Subscribe for More Information
09:12 EDTSHPGShire multiple poised to expand, says SunTrust
SunTrust believes that Shire's rare disease unit will account for 40% of its 2020 sales, versus the company's estimate of about 35%. As a result, the firm expects the company's multiple to "re-rate." The firm thinks that the company's long-term growth outlook is underappreciated, and it keeps a $262 price target and Buy rating on the shares.
February 13, 2015
17:52 EDTSHPGThird Point gives quarterly update on stakes
Subscribe for More Information
09:08 EDTSHPGShire price target raised to $280 from $240 at Susquehanna
Subscribe for More Information
09:07 EDTABBVDeutsche Bank biotech analyst holds an analyst/industry conference call
Biotech Analyst Karnauksas discusses AbbVie's product pipeline in an Analyst/Industry conference call to be held on February 13 at 10 am.
08:19 EDTSHPGAckman noncommittal on McDonald's rumors, Bloomberg reports
Subscribe for More Information
06:28 EDTSHPGSources: Shire takes initial steps towards Salix bid, Reuters reports
According to sources, Shire (SHPG) is beginning to take steps towards a bid for Salix Pharmaceuticals (SLXP), including evaluating how to secure financing for a potential bid, Reuters reports. Bloomberg previously reported that Valeant (VRX) is weighing a bid of over $150 per share for Salix. Reference Link
06:13 EDTSHPG, ABBVShire says $1.6B break fee from AbbVie is not taxable, Financial Times reports
Subscribe for More Information
February 12, 2015
13:59 EDTSHPGValeant secures financing for Salix takeover, Bloomberg says
Subscribe for More Information
08:15 EDTSHPGShire sees FY15 product sales growth mid-to-high single digits
Shire said that on a Constant Exchange Rate basis, it expects product sales growth in the mid-to-high single digits. When excluding the effect of INTUNIV product sales, it anticipates low double digit product sales growth on a CER basis. Based on actual exchange rates, the company sees low-to-mid single digit product sales growth in 2015. This rate of product sales growth is lower than we saw in 2014 as we compare against the initial year of CINRYZE product sales and expect significantly lower INTUNIV sales following its December 2014 loss of exclusivity. Additionally, it expects product sales growth in 2015 will be held back by approximately three to four percentage points by foreign exchange headwinds from the strengthening U.S. dollar, which it noted particularly impacts ELAPRASE, REPLAGAL and VPRIV sales. Non GAAP gross margin is expected to be in line with 2014, which was 85.8%. outlook includes our preliminary assessment of the effect of the NPS Pharmaceuticals (NPS) acquisition, which it expects to close in Q1.
07:19 EDTSHPGShire raises dividend to 22.92c from 19.93c
In respect of the six months ended December 31, 2014 the board has resolved to pay an interim dividend of 19.09c per ordinary share, vs. 16.93c per ordinary share for 2013. Dividend payments will be made in US Dollars to holders of ADSs. A dividend of 57.27c per ADS will be paid on April 14 to shareholders on the register as at the close of business on March 13. Together with the first interim payment of 3.83c per ordinary share, this represents total dividends for 2014 of 22.92 US cents per ordinary share, an increase of 15% in US Dollar terms vs. 2013's 19.93c per ordinary share.
07:02 EDTSHPGShire reports Q4 EPS $2.63, consensus $2.68
Subscribe for More Information
06:34 EDTABBVEnanta partner AbbVie submits hepatitis C NDA to Japanese regulating agency
Subscribe for More Information
05:28 EDTABBVAbbVie submits new drug application in Japan for hepatitis C treatment
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use